Shilpa Medicare arm Raichur API facility gets GMP Certification from ANVISA-Brazil
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-07-10 06:01 GMT | Update On 2024-07-16 15:31 GMT
USFDA inspection
Advertisement
Karnataka: Shilpa Medicare Limited's 100 percent subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has received GMP Certification from ANVISA-Brazil.
The GMP inspection was conducted at the facility from April 15-April 19, 2024.
The facility is involved in manufacturing various oncology and nononcology APIs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.